Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.
Frequently asked questions
What sector does Cardax Inc (CDXI) operate in?
Cardax Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Cardax Inc (CDXI) current stock price?
As of the latest data, Cardax Inc stock price is $0.00, with a previous close of $0.00.
What is Cardax Inc (CDXI) current market capitalization?
Cardax Inc market cap is approximately 80.25.
What is Cardax Inc (CDXI) Earnings Per Share (EPS)?
The trailing EPS is -$3.54.
Does Cardax Inc (CDXI) pay dividends?
No. Cardax Inc does not pay a dividend.
What is Cardax Inc (CDXI) beta (volatility) score?
Cardax Inc has a beta of 39.483, indicating very high volatility compared to the market.